VONJO Drug Patent Profile
✉ Email this page to a colleague
When do Vonjo patents expire, and when can generic versions of Vonjo launch?
Vonjo is a drug marketed by Cti Biopharma Corp and is included in one NDA. There are three patents protecting this drug.
This drug has seventy-seven patent family members in twenty-seven countries.
The generic ingredient in VONJO is pacritinib citrate. One supplier is listed for this compound. Additional details are available on the pacritinib citrate profile page.
DrugPatentWatch® Generic Entry Outlook for Vonjo
Vonjo will be eligible for patent challenges on February 28, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 25, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VONJO?
- What are the global sales for VONJO?
- What is Average Wholesale Price for VONJO?
Summary for VONJO
| International Patents: | 77 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 3 |
| Drug Prices: | Drug price information for VONJO |
| What excipients (inactive ingredients) are in VONJO? | VONJO excipients list |
| DailyMed Link: | VONJO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VONJO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for VONJO
US Patents and Regulatory Information for VONJO
VONJO is protected by six US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VONJO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VONJO
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
FDA Regulatory Exclusivity protecting VONJO
TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VONJO
When does loss-of-exclusivity occur for VONJO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4724
Patent: SAL DE CITRATO 11-(2-PIRROLIDIN-1-IL-ETOXI)-14,19-DIOXA-5,7,26-TRIAZA-TETRACICLO (19.3.1.1(2,6).1(8,12) HEPTACOSA-1-(25),2(26),3,5,8,10,12 (27),16,21,23-DECAENO
Estimated Expiration: ⤷ Sign Up
Patent: 4133
Patent: SAL DE CITRATO DE 11-(2-PIRROLIDIN-1-IL-ETOXI)-14,19-DIOXA-5,7,26-TRIAZA-TETRACICLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09325147
Patent: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0922736
Patent: sal de citrato de 11-(pirrolidin-1-il-etóxi)-14-dioxina-5-7,26-triaza-tetraciclo [19.3.1.1(2.6).1(8.12)] ehptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 46058
Patent: SEL DE CITRATE DE 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE (11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2282148
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0150428
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 76499
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 76499
Patent: SEL DE CITRATE DE 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE (11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 61877
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9379
Patent: מלח ציטראט של 11-(2-פירולידינ-1-יל-אתוקסי)-19,14-דיאוקסא-26,7,5-טריאזא-טטראציקלו[1.1.3.19(6,2)1(12,8)]הפטאקוסא-1(25),2(26),12,10,8,5,3(27)j23,21,16-דקאן (11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 69748
Estimated Expiration: ⤷ Sign Up
Patent: 12511571
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 0005
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 11006206
Patent: SAL DE CITRATO DE 11-(2-PIRROLIDIN-1-IL-ETOXI)-14,19-DIOXA-5,7,26- TRIAZA-TETRACICLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5 ,8,10,12(27),16,21,23-DECAENO. (11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYC LO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16 ,21,23-DECAENE CITRATE SALT.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 3223
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1 (2,6).1(8, 12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 76499
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 76499
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 27970
Patent: ЦИТРАТ 11-(2-ПИРРОЛИДИН-1-ИЛ-ЭТОКСИ)-14,19-ДИОКСА-5,7,26-ТРИАЗАТЕТРАЦИКЛО[19.3.1.1(2,6).1(8,12)]ГЕПТАКОЗА-1(25),2(26),3,5,8,10,12(27),16,21,23-ДЕКАЕНА (11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE)
Estimated Expiration: ⤷ Sign Up
Patent: 11126173
Patent: ЦИТРАТ 11-(2-ПИРРОЛИДИН-1-ИЛ-ЭТОКСИ)-14,19-ДИОКСА-5,7,26-ТРИАЗА-ТЕТРАЦИКЛО [19.3.1.1 (2,6).1(8,12)]ГЕПТАКОЗА-1-( 25),2( 26),3,5,8,10,12( 27),16,21,23-ДЕКАЕНА
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 1907
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1104032
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1729918
Estimated Expiration: ⤷ Sign Up
Patent: 110106344
Patent: 11- (2-PYRROLIDIN-1-YL-ETHOXY) -14, 19-DIOXA-5, 7, 26-TRIAZA-TETRACYCLO [19. 3. 1. 1 (2, 6) 1 (8, 12)]HEPTACOSA-1 (25), 2 (26), 3, 5, 8, 10, 12 (27) J16, 21, 23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 36558
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 49705
Estimated Expiration: ⤷ Sign Up
Patent: 1028426
Patent: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VONJO around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
